US5204356AExpiredUtility

Treatment of anxiety

Assignee: GLAXO GROUP LTDPriority: Jul 24, 1985Filed: Jan 29, 1992Granted: Apr 20, 1993

Est. expiryJul 24, 2005(expired)· nominal 20-yr term from priority

Inventors:Michael B. Tyers

A61K 31/40A61K 31/445A61K 31/46A61K 31/435A61K 31/55

PatentIndex Score

Cited by

References

Claims

Abstract

The invention relates to the use of compounds which act as 5-hydroxytryptamine (5-HT) antagonists at 5-HT "M" receptors in the treatment of anxiety.

Claims

exact text as granted — not AI-modified

I claim: 
     
       1. A method for the treatment of anxiety in a human or animal subject suffering from or susceptible to anxiety which comprises administering to the human or animal subject an effective amount for the treatment of anxiety in said subject of an azabicyclo derivative which acts as an antagonist of 5-hydroxytryptamine (5-HT) at 5-HT &#34;M&#34; receptors, wherein said azabicyclo derivative is a conjugate formed from an indole derivative connected by an amide group to a tropyl group; or a physiologically acceptable salt or solvate thereof. 
     
     
       2. A method according to claim 1 wherein said azabicyclo derivative or a physiologically acceptable salt or solvate thereof is administered in a dose of 0.5 μg to 20 mg from 1 to 4 times per day. 
     
     
       3. A method according to claim 2 wherein the dose is from 0.05 mg to 10 mg from 1 to 4 times per day. 
     
     
       4. A method according to claim 1 wherein said azabicyclo derivative is administered orally, buccally, parenterally, rectally or as a depot preparation. 
     
     
       5. A method according to claim 1 wherein said azabicyclo derivative is administered orally.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.